USNA

Business Context and Reporting Period

Company: USANA Health Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 29, 2001
Business Overview: USANA develops, manufactures, and distributes nutritional, personal care, and weight management products via a network marketing system. As of the reporting date, the company had approximately 86,000 independent "Associates" and 77,000 "Preferred Customers" globally. Primary markets include North America (82.4% of sales), Australia-New Zealand (12.5%), and Hong Kong (4.6%). Japan operations began in October 2001.

Key Financial Metrics (Fiscal Year 2001)

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 7.2% to $114.3 million, driven by a 7.5% decline in the Associate base and weaker foreign currencies relative to the U.S. dollar.
• Profitability Compression: Net earnings margin dropped to 1.9% from 2.3% in 2000. While gross profit margin improved slightly to 71.3%, operating expenses as a percentage of sales increased due to fixed costs associated with new Japan operations and declining sales volume.
• Associate Base Shift: The number of Associates declined from 93,000 to 86,000, while Preferred Customers increased slightly from 76,000 to 77,000. Management attributes the Associate decline to a 2000 pricing initiative that shifted the customer base toward non-selling consumers.
• Liquidity Tightening: Working capital decreased significantly to $350,000 due to capital expenditures ($6.6M in property and equipment) and increased current debt maturities.

Guidance, Outlook, and Material Events

Proposed Asset Sale (Subsequent Event)

On March 21, 2002, USANA entered into an agreement to sell substantially all operating assets and assume liabilities to USANA Acquisition Corp. (UAC), a company wholly owned by Gull Holdings (controlled by CEO Dr. Myron Wentz). Key terms include:

• Purchase Price: Approximately $25 million.
• Consideration: Includes redemption of 4.8 million shares of USANA stock owned by Gull Holdings ($7.7M value) and a $5.0 million promissory note to USANA.
• Post-Transaction Structure: UAC will continue the USANA business. The remaining shell company will be renamed "Innova Ventures, Inc." and will pursue new acquisitions. Innova will retain real estate (leased to UAC) and approximately $3.0 million in cash.
• Management Changes: Dr. Wentz and David Wentz will resign from USANA to manage UAC. Gilbert Fuller and John McCandless will remain as the sole employees of the shell company.

Risks and Contingencies

• Regulatory Scrutiny: Network marketing is subject to intense government regulation (FTC, FDA). Violations by Associates or changes in laws could materially affect operations.
• Foreign Currency: Significant exposure to currency fluctuations (approx. 42% of sales outside the U.S.) with no hedging instruments in place as of year-end.
• Key Personnel: Heavy reliance on Dr. Wentz, who receives no salary but controls 49.5% of voting stock.

Investor Verification Checklist

• Transaction Approval: Verify the outcome of the shareholder vote required to approve the sale of assets to UAC and the subsequent dissolution of the current business entity.
• Debt Covenants: Confirm continued compliance with credit facility covenants, given the tight working capital position ($350k) and upcoming principal payments on the term loan starting March 2002.
• Associate Retention: Monitor future reports for the effectiveness of the "Year of the Business" initiative to reverse the decline in the Associate base.
• Japan Market Performance: Assess whether sales in the new Japan market reach expected levels to offset the decline in mature markets like Australia-New Zealand.
• Related Party Transactions: Review the final terms of the asset sale to ensure the valuation ($25M) and the treatment of the $5M promissory note are favorable to remaining shareholders.